Authors
G P A da Silva, P J C Ferraz, A C S Ribeiro, R P Cavalheiro, M A S Pinhal, C M Melo
Published in
Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas. Volume 59. Pages e15306. Epub Nov 09, 2026.
Abstract
Breast cancer is one of the most lethal malignancies worldwide, with late diagnosis representing a major contributor to its high mortality rate. Consequently, novel biomarkers are being investigated to facilitate earlier detection and better clinical outcomes. Versican, a large chondroitin sulfate proteoglycan found in the extracellular matrix, interacts with diverse proteins and carbohydrates, thereby modulating essential cellular processes such as proliferation, migration, and invasion. These features make versican a promising target in oncological research. In this study, we analyzed versican expression in both surgically resected breast tissue and peripheral blood from breast cancer patients and healthy donors, aiming to evaluate its relevance as a biomarker and its role in tumor progression. To achieve this, we combined in silico analyses with ex vivo investigations using immunohistochemistry in breast tissues and real-time PCR in the mononuclear fraction. Our findings indicated that versican was significantly upregulated in breast cancer patients compared to healthy controls, in both tissue and blood samples. Taken together, these results underscore the potential of versican as a biomarker for breast cancer.
PMID:
43018010
Bibliographic data and abstract were imported from PubMed on 12 Nov 2026.
Read full publication at:
Please sign in
to see all details.
Advertisement
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 7
- Comments 0